Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse: "The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery." In April 2026, Eli Lilly's retatrutide delivered 28.7% mean weight loss, the first non-surgical therapy to match bariatric outcomes. But the milestone didn't end the race. It changes it. Everyone is focused on the 28.7%," said Will Rosellini - Chief IP Officer at PatentVest. "But that number is ...